Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992

Arthritis and Rheumatism

Volumn 42, Issue 1, 1999, Pages 46-50

  Uramoto, Kristine M ^a   Michet Jr , Clement J ^a   Thumboo, Julian ^a   Sunku, Jayasimha ^a   O'Fallon, W Michael ^a   Gabriel, Sherine E ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; FEMALE; HUMAN; INCIDENCE; MALE; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; CHILD; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREVALENCE; SURVIVAL RATE;

EID: 0032895063     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199901)42:1<46::AID-ANR6>3.0.CO;2-2     Document Type: Article

References (25)

1. Cohen AS, Reynolds WE, Franklin EC, Kulka JP, Ropes MW, Shulman LE, et al. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 1971;21:643-8.
2. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
3. Michet CJ Jr, McKenna CH, Elveback LR, Kaslow RA, Kurland LT. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1985;60:105-13.
4. Kurland LT, Hauser WA, Ferguson RH, Holley KE. Epidemiology features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus. Mayo Clin Proc 1969;44:649-63.
5. Kurland LT, Molgaard CA. The patient record in epidemiology. Sci Am 1981;245:54-63.
6. Sanchez-Guerrero J, Karlson EW, Liang MH, Hunter DJ, Speizer FE, Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997; 40:804-8.
7. Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995;122:430-1.
8. Zamansky GB. Sunlight-induced pathogenesis in systemic lupus erythematosus. J Invest Dermatol 1985;85:179-80.
9. Petzelbauer P, Binder M, Nikolakis P, Ortel B, Honigsmann H. Severe sun sensitivity and the presence of antinuclear antibodies in patients with polymorphous light eruption-like lesions. J Am Acad Dermatol 1992;26:68-74.
10. Brown K, Petri M, Goldman D. Cutaneous manifestations of SLE: associations with other manifestations of SLE and with smoking [abstract]. Arthritis Rheum 1995;38 Suppl 6:R27.
11. Fessel WJ. Systemic lupus erythematosus in the community: incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch Intern Med 1974;134:1027-35.
12. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus: race and gender differences. Arthritis Rheum 1995;38:1260-70.
13. Jonsson H, Nived O, Sturfelt G, Silman A. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol 1990;29:185-8.
14. Hopkinson ND, Doherty M, Powell RJ. The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989-1990. Br J Rheumatol 1993;32:110-5.
15. Gudmundsson S, Steinsson K. Systemic lupus erythematosus in Iceland 1975 through 1984: a nationwide epidemiological study in an unselected population. J Rheumatol 1990;17:1162-7.
16. Swaak AJ, Nieuwenhuis EJ, Smeenk RJ. Changes in clinical features of patients with systemic lupus erythematosus followed prospectively over 2 decades. Rheumatol Int 1992;12:71-5.
17. Nived O, Sturfelt G, Wollheim F. Systemic lupus erythematosus in an adult population in southern Sweden: incidence, prevalence, and validity of ARA revised classification criteria. Br J Rheumatol 1985;24:147-54.
18. Hopkinson ND, Doherty M, Powell RJ. Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. Ann Rheum Dis 1994;53:676-80.
19. Hochberg MC. Systemic lupus erythematosus. Rheum Dis Clin North Am 1990;16:617-39.
20. Hochberg MC, Perlmutter DL, Medsger TA, Steen V, Weisman MH, White B, et al. Prevalence of self-reported physician-diagnosed systemic lupus erythcmatosus in the USA. Lupus 1995;4:454-6.
21. Lahita RG. Special report: adjusted lupus prevalence. Results of a marketing study by the Lupus Foundation of America. Lupus 1995;4:450-3.
22. Gladman DD. Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1996;8:430-7.
23. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus: patient characteristics associated with poorer outcomes. Arthritis Rheum 1995;38:274-83.
24. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus: results from a single center. III. Improved survival over 24 years. J Rheumatol 1997;24: 1061-5.
25. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-74.